ES2653265T3 - Morfinanos sustituidos y el uso de éstos - Google Patents

Morfinanos sustituidos y el uso de éstos Download PDF

Info

Publication number
ES2653265T3
ES2653265T3 ES13823996T ES13823996T ES2653265T3 ES 2653265 T3 ES2653265 T3 ES 2653265T3 ES 13823996 T ES13823996 T ES 13823996T ES 13823996 T ES13823996 T ES 13823996T ES 2653265 T3 ES2653265 T3 ES 2653265T3
Authority
ES
Spain
Prior art keywords
cycloalkyl
cycloalkenyl
heterocycle
alkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13823996T
Other languages
English (en)
Inventor
Andrew KASSICK
Laykea Tafesse
Jeffrey Lockman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Application granted granted Critical
Publication of ES2653265T3 publication Critical patent/ES2653265T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto que tiene la Fórmula I-A: **(Ver fórmula)** o una sal o solvato farmacéuticamente aceptable de éste, en el que: R1 es hidrógeno, OH, halo, ciano, carboxi, o aminocarbonilo; o alquilo, alquenilo, alquinilo, alcoxi, alqueniloxi, o alquiniloxi, cualquiera de los cuales está sustituido opcionalmente con 1, 2, ó 3 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en hidroxi, halo, haloalquilo, amino, alquilamino, dialquilamino, carboxi, alcoxi, alcoxicarbonilo, arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo, en el que el arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo están sustituidos opcionalmente con 1, 2, ó 3 grupos R11a seleccionados independientemente; R2 es: (a) hidrógeno o carboxamido; o (b) alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, heterociclo, arilo, heteroarilo, (cicloalquil)alquilo, (cicloalquenil)alquilo, (heterociclo)alquilo, arilalquilo, heteroarilalquilo, alquilcarbonilo, alcoxicarbonilo, (arilalcoxi)carbonilo, o (heteroarilalcoxi)carbonilo, cualquiera de los cuales está sustituido opcionalmente con 1, 2, ó 3 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en hidroxi, alquilo, halo, haloalquilo, amino, alquilamino, dialquilamino, carboxi, alcoxi, alcoxicarbonilo, arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo, en el que el arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo están sustituidos opcionalmente con 1, 2, ó 3 grupos R11a seleccionados independientemente; R3 es hidrógeno, OH, o halo; o alcoxi, alquilamino, o dialquilamino, cualquiera de los cuales está sustituido opcionalmente con 1, 2, ó 3 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en hidroxilo, halo, haloalquilo, amino, alquilamino, dialquilamino, carboxi, alcoxi, alcoxicarbonilo, arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo, en el que el arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo están sustituidos opcionalmente con 1, 2, ó 3 grupos R11a seleccionados independientemente; R4a1 se selecciona del grupo que consiste en alquilo C3-C6, arilalquilo, (cicloalquil)alquilo, alcoxi C3-C6, aralquiloxi, -N(H)COR4c, -CH2C(>=O)NR4dR4e, -N(H)SO2R4f, **(Ver fórmula)** ...
ES13823996T 2012-12-28 2013-12-23 Morfinanos sustituidos y el uso de éstos Active ES2653265T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746878P 2012-12-28 2012-12-28
PCT/IB2013/002883 WO2014102593A1 (en) 2012-12-28 2013-12-23 Substituted morphinans and the use thereof

Publications (1)

Publication Number Publication Date
ES2653265T3 true ES2653265T3 (es) 2018-02-06

Family

ID=50000021

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13823996T Active ES2653265T3 (es) 2012-12-28 2013-12-23 Morfinanos sustituidos y el uso de éstos

Country Status (9)

Country Link
US (2) US8946255B2 (es)
EP (1) EP2941431B1 (es)
JP (1) JP6159417B2 (es)
AR (1) AR094646A1 (es)
CA (1) CA2896202A1 (es)
ES (1) ES2653265T3 (es)
IL (1) IL239643A0 (es)
TW (1) TW201441199A (es)
WO (1) WO2014102593A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02367B (me) 2010-09-21 2016-06-20 Purdue Pharma Lp Analozi buprenorfina kao agonisti i/ili antagonisti opioidnog receptora
EP2917182B1 (en) 2012-11-09 2018-01-03 Purdue Pharma LP Benzomorphan analogs and the use thereof
WO2014087226A1 (en) 2012-12-07 2014-06-12 Purdue Pharma L.P. Buprenorphine analogs as opiod receptor modulators
US8987287B2 (en) 2012-12-14 2015-03-24 Purdue Pharma L.P. Spirocyclic morphinans and their use
ES2631197T3 (es) 2012-12-14 2017-08-29 Purdue Pharma Lp Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes
EP2951160B1 (en) 2013-01-31 2019-04-24 Purdue Pharma LP Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
US9994571B2 (en) 2013-12-26 2018-06-12 Purdue Pharma L.P. 10-substituted morphinan hydantoins
WO2015097548A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
JP6353543B2 (ja) 2013-12-26 2018-07-04 パーデュー、ファーマ、リミテッド、パートナーシップ 環縮小モルフィナン及びその使用
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
US10550088B2 (en) 2013-12-27 2020-02-04 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
CA2950567A1 (en) 2014-05-27 2015-12-03 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
US10202382B2 (en) 2014-06-13 2019-02-12 Purdue Pharma L.P. Azamorphinan derivatives and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
US10246436B2 (en) * 2015-09-02 2019-04-02 Trevena, Inc. 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
GB201719667D0 (en) * 2017-11-27 2018-01-10 Johnson Matthey Plc Process
WO2021015109A1 (ja) 2019-07-19 2021-01-28 日本ケミファ株式会社 フェノール誘導体の製造方法
CN117062815A (zh) 2021-03-22 2023-11-14 纽罗克里生物科学有限公司 Vmat2抑制剂及使用方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2178010A (en) 1937-02-03 1939-10-31 Small Lyndon Frederick Nuclear substituted derivatives of the morphine series and methods for their preparation
GB1031364A (en) 1962-04-09 1966-06-02 Shionogi & Co Improvements in or relating to 6-hydroxymorphinan derivatives and their production
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
CA1093070A (en) * 1978-02-10 1981-01-06 Michael P. Kotick 8.beta.-ALKYL-SUBSTITUTED MORPHINAN-6-ONE COMPOUNDS
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
CA1135692A (en) * 1979-05-21 1982-11-16 Michael P. Kotick 7-methyl and 7-methyl-8-lower alkyl b/c cis or trans morphinan-6-one compounds
US4242514A (en) 1979-10-17 1980-12-30 Miles Laboratories, Inc. Method for the introduction of a methyl group into the 7 position of the morphinan nucleus
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4362733A (en) 1981-06-29 1982-12-07 Miles Laboratories, Inc. N-Cyclopropylmethyl-14-ethoxymorphinan-6-one compounds exhibiting mixed analgesic/narcotic antagonist activity and precursors therefore
US4423221A (en) 1982-06-10 1983-12-27 Sisa Pharmaceutical Laboratories, Inc. 7-Carboethoxy-morphinan-6-one compounds
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4912114A (en) 1988-03-18 1990-03-27 Sandoz Ltd. Morphinan derivatives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
PL327943A1 (en) 1996-01-10 1999-01-04 Smithkline Beecham Spa Condensed heterocyclic derivatives of morphonoide (ii)
US6067749A (en) 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
EP0829481A1 (en) 1996-09-16 1998-03-18 Pfizer Inc. Morphinan hydroxamic acid compounds
EP1210084A4 (en) 1999-08-13 2002-11-13 Southern Res Inst PYRIDOMORPHINANS, THIENOMORPHINANS AND THEIR USE
IL157662A0 (en) * 2001-03-02 2004-03-28 Euro Celtique Sa N-but-3-enyl norbuprenorphine and its use as analgesic
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
JP2006502190A (ja) 2002-09-18 2006-01-19 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ デルタ−オピオイド受容体に選択的なオピエート類似物
CA2541014A1 (en) 2003-10-01 2005-04-14 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
GB0421687D0 (en) 2004-09-30 2004-11-03 Johnson Matthey Plc Preparation of opiate analgesics
AU2006215823A1 (en) 2005-02-16 2006-08-24 Micromet Ag Use of activated polymers for separation of protein and polypeptide multimers
CN101340911B (zh) 2005-12-21 2013-01-02 东丽株式会社 镇咳剂
BRPI0719327A2 (pt) 2006-11-22 2014-02-04 Progenics Pharm Inc N-óxidos de análogos de 4,5-epóxi-morfinano
CN101210016B (zh) 2006-12-29 2011-07-20 中国科学院上海药物研究所 一类杂环并吗啡喃类化合物、制备方法及用途
JP2008179554A (ja) 2007-01-24 2008-08-07 Toray Ind Inc ピロール縮合モルヒナン誘導体およびその医薬用途
EP2148864A2 (en) 2007-05-16 2010-02-03 Rensselaer Polytechnic Institute Fused-ring heterocycle opioids
US20100222309A1 (en) 2007-10-05 2010-09-02 Toray Industries, Inc. Skin property-improving therapeutic agent comprising a morphinan derivative or any of its pharmacologically permissible acid addition salts as an active ingredient
WO2009059048A2 (en) 2007-10-30 2009-05-07 The Regents Of The University Of Colorado (+)-opioids and methods of use
WO2009067275A1 (en) 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxides of 4,5-epoxy-morphinanium analogs
KR101274107B1 (ko) 2007-11-30 2013-06-13 퍼듀 퍼머 엘피 벤조모르판 화합물
JP5688974B2 (ja) 2007-12-17 2015-03-25 マリンクロッド エルエルシー （＋）−オピエートの生成のためのプロセスおよび化合物
ES2569655T3 (es) 2007-12-17 2016-05-12 Mallinckrodt Llc Procedimientos para la producción de compuestos de (+)-'nal' morfinano
EP2703404A1 (en) * 2008-07-30 2014-03-05 Purdue Pharma L.P. Buprenorphine analogs
CA2768236C (en) * 2009-07-16 2018-05-22 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
WO2012005795A1 (en) 2010-07-08 2012-01-12 Alkermes, Inc. Process for the synthesis of substituted morphinans
MX338392B (es) 2010-11-12 2016-04-13 Shionogi & Co Cristal de derivado de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo.
EP2655332B1 (en) 2010-12-23 2016-07-13 Phoenix Pharmalabs, Inc. Novel morphinans useful as analgesics
US9370511B2 (en) 2011-08-26 2016-06-21 Eckhard LAMMERT Morphinan-derivatives for treating diabetes and related disorders
WO2013035833A1 (ja) 2011-09-09 2013-03-14 学校法人北里研究所 モルヒナン誘導体
CA2894971C (en) 2012-12-14 2018-06-26 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof

Also Published As

Publication number Publication date
US20140187573A1 (en) 2014-07-03
US8946255B2 (en) 2015-02-03
JP6159417B2 (ja) 2017-07-05
US20150175571A1 (en) 2015-06-25
IL239643A0 (en) 2015-08-31
EP2941431B1 (en) 2017-10-25
CA2896202A1 (en) 2014-07-03
WO2014102593A1 (en) 2014-07-03
AR094646A1 (es) 2015-08-19
US9388162B2 (en) 2016-07-12
JP2016509588A (ja) 2016-03-31
TW201441199A (zh) 2014-11-01
EP2941431A1 (en) 2015-11-11

Similar Documents

Publication Publication Date Title
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
CR20170066A (es) Compuestos aminopirimidinilo como inhibidires de jak
PH12016501007A1 (en) Substituted benzamides and methods of use thereof
AR094647A1 (es) Análogos de 7,8-morfinano cíclico
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
NZ732810A (en) Picolinamides and other compounds
MX2015010775A (es) Benzoxazoles sustituidos y metodos para usarlos.
MY169043A (en) New dihydroquinoline-2-one derivatives
MX2016007539A (es) Compuestos herbicidas de pirimidiniloxi benceno sustituido.
MX371337B (es) Compuestos para protección de células.
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
MY172860A (en) Dimethyl-benzoic acid compounds
JO3509B1 (ar) معدلات p2x7
MX368178B (es) Compuestos de ácido dimetilbenzoico.
MX2015017156A (es) Inhibidores de bace.
PH12015500009B1 (en) Phenoxyethyl piperidine compounds
MX353190B (es) Derivados de isoquinolina y naftiridina.
ES2721658T3 (es) 3,4-dihidro-1h-[1,8]naftiridinonas sustituidas con ciclopenta[c]pirrol antibacterianas
ES2553030T3 (es) Compuestos plaguicidas
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
PH12016500152A1 (en) Novel triazine derivative
MX2016007985A (es) Compuestos de fluorofenilpirazol.